No Data
No Data
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research
Zyversa Therapeutics Announces Published Data Supporting Potential Of Inflammasome ASC Inhibitor IC 100 To Slow Progression Of Parkinson's Disease
Express News | Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor Ic 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status
Express News | Zyversa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome Asc Inhibitor Ic 100’s Development Status
12 Health Care Stocks Moving In Wednesday's Intraday Session